Precipio, Inc.
PRPO Healthcare Diagnostics & Research
Precipio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.0 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 24.2%, EPS fell 340.0%, free cash flow grew 79.6% and total debt rose 47.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PRPO
Precipio, Inc. (PRPO) P/E ratio
Precipio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.2× (August 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNR Burning Rock Biotech Limited Sponsored ADR compare | n/m |
| MDXHF MedX Health Corp. compare | n/m |
| MBAI MBody AI Ltd. compare | n/m |
| PMD Psychemedics Corporation compare | n/m |
| QUCY Quantum Cyber N.V compare | n/m |
| MDXH MDxHealth SA compare | n/m |
| PRPO Precipio, Inc. | n/m |
| IMDX Insight Molecular Diagnostics Inc. compare | n/m |
| ADVB Advanced Biomed Inc. compare | 0.8× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)